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Abstract
Using the method given by GOLDSTEIN (1961)9 for the determination of serum beta-glucuronidase
activity, this value was determined in both normal and patients with epilepsy, neuroses, psychoses
and multiple sclerosis. Of the patient groups examined, the group of those suffering from epilepsy
is the only one showing any difference of statistical significance for all four methods of determi-
nation. The group of patients suffering from neuroses differs significantly from the normal group
as regards the results got by the method of heat coagulation for removal of the proteins. The ma-
terial is however too small to provide any explanation of the results, but it appears to show that a
determination of serum glucuronidase activity may be of interest in groups of diseases other than
malignant tumors.
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In recent years, serum beta-glucuronidase determinations have been em-
ployed by various workers in the diagnosis of cancer of the breast and of the
female genitals (COHEN et al., 19511 •2, ODELL et al., 19498, FI;:;HMANN, 1947\
FISHMANN et al., 1951)6.6. In particular, a study has been made of the changes
which occur in the enzyme activity in oestrogen therapy. As the determination
does not appear to have been employed in the investigation of other disease
groups, it was decided to include the procedure as a step in a series of studies
on multiple sclerosis.
TALALAy (1946)7 introduced phenolphthalein-mono-beta-glucuronide as a
substrate in the determination of serum beta-glucuronidase. The enzymatic
splitting of this substance results in a pink colour which can be measured by
spectrophotometry in alkaline solution. There is no actual deproteinisation in
this method, and the protein precipitated during the analysis is removed by
centrifugation before making the actual reading. This method has been discussed
by various workers, with particular reference to whether a deproteinisation is
involved or not.
FISHMANN et al. (1948)8 used trichloracetic acid as a deproteinising agent.
In a study of 16 normal subjects, these workers found an enzyme activity vary-
ing from 0,....,,230 units/lOO ml serum, with a mean value of 101 units. This
value is lower than the values found by GOLDSTEIN (19G1)9 and also lower than
in the normal material presented here. Further, these workers showed that
there are not very great amounts of beta-glucuronidase in erythrocytes, but a
high concentration in both granulocytes and lymphocytes. The presence of the
enzyme is also demonstrated in saliva, gastric juice, tears, urine and the cerebro-
spinal fluid.
FISHMANN et al., 1950 (s) modification found extensive application, but a
few workers (Moore et al.,n 1950; Mills et al.,t° 1953) demonstrated that the
precipitated protein binds some of the coloured substance, so that lower values
are obtained.
GoLDSTEIN (1961)9 discusses a number of studies of these observations, and
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finds that while high values are obtained provided the proteins are not precipita-
ted (l) or are precipitated· by acetone (IV), considerably lower values are got
if the proteins are precipitated by trichloracetic acid (ll) or by boiling (heat
coagulation) (Ill).
The methods given by GOLDSTEIN (I-IV) have been followed in the present
study, and beta-glucuronidase determined in the four experiments set up in
parallel.
The material includes a normal material of 8 men and 18 women, 12 pati-
ents suffering from multiple sclerosis, 8 patients with epilepsy, 7 with mental
diseases and 14 with neuroses.
The patient material is not selected, but taken as representing an average of
these groups, with the exception of the 12 patients with multiple selerosis, who
all come from the Sanatorium for the Treatment of Multiple Sclerosis, Haslev.
METHODS
This is practically identical with that given by GOLDSTEIN9•
Acetate buffer solution, 0.1 M. To make pH 4.0 solution, sodium acetate(CHsCOONa·3H20) 2.028 g and glacial acetic acid 4.87 ml, and for pH 4.5 solu-
tion 5.785 g and 3.25 ml respectively, are diluted to 1,000 ml and adjusted on
pH meter.
Substrate : phenolphthalein mono-beta-glucuronic acid, 0.01 M. "Sig-
ma" reagents are used in the preparation following the instructions supplied(Sigma Bulletin, 105).
Glycol buffer, 0.4 M, pH 10.55. 16.30 g glycol and 12.65 g sodium chlo-
ride are dissolved in water, 10.9 concentrated NaOH is added and the volume
diluted to 1,000 ml. Adjust on pH meter.
Glycol buffer-alkali mixture. 200 ml glycol buffer is mixed with 100 ml0.25 NNaOH.
Trichloracetic acid, 5 per cent. 1 ml phenolphthalein reagent, 250,'J.g in
80 per cent alcohol.
Procedure:
In two test-tubes, place 0.6 ml haemolysis-free serum plus 4.8 ml of 0.1 M
acetate buffer, pH 4.5. Add 0.6 ml of substrate to the one tube, stopper the
tubes and place them in a water-bath at 37°C for 24 hours, remove them from
the water-bath and then add 0.6 ml substrate to the other tube (control).
These samples are now used immediately for the following four analyses:
I. Proteins not removed: Pipette 1 ml sample and 1 ml control into two
centrifuge tubes. Prepare a standard consisting of 0.1 ml phenolphthalin standard,
0.8 ml 0.1 M acetate buffer pH 4.5 and 0.1 ml distilled water, together with a
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blind sample, analogous with the standard, except that the phenolphthalein solu-
tion is replaced by 0.1 ml distilled w~ter. Readings are made, including the blind
sample, in a Beckmann DU spectrophotometer at 540 mp..
I I. Proteins removed by trichloracetic acid: One sample and 1 ml
control are pipetted into two centrifuge tubes containing 1 ml of 5 per cent
trichloracetic acid, the contents then mixed and centrifuged. The supematant
is decanted into a fresh centrifuge tube. The sediment is washed with 0.5 ml
distilled water, centrifuged, and the supematant decanted to the remainder of
the sample. \Vashing is repeated. Standard and blind are prepared as described
under I, and supplemented further with 1 ml of 5 per cent trichloracetic acid.
Now add 4 ml glycol-alkali mixture to all tubes, and as described in 1.
I I J. Proteins removed by heat coagulation: Two ml of sample and
control in centrifuge tubes are immersed in boiling water for 1 minute. They
are then centrifuged and 1 ml of the supematant treated as described in 1.
IV. Proteins removed by acetone: To 2 ml of sample and control (i. a.
the remainder in the tubes) add 2 ml acetone, mix, centrifuge, transfer 2 ml of
the supernatant to clean tubes. Standard and blind sample are prepared as des-
cribed in I, and 1 ml acetone added. Then add 4 ml glycol-alkali mixture, mix
carefully and read as described in 1.
Calculation:
Extinction of sample X phenolphthalein X 100 X 1 _
Extinction of standard in standard (p.g) serum (ml) incubation time(hr)
= units of glucuronidase/lOO ml serum
One unit beta-glucuronidase is the amount that releases 1p.g phenolphthalein
per hour under the given experimental conditions.
RESULTS
Table 1 shows the statistical evaluation of the results. Figures 1--4 gives
the results from all experiments made in diagrams.
As already mentioned, the method used in the present investigation was
that given by GOLDSTEIN (1961)9. The investigator reported the results of analy-
ses made on 6 subjects. Unfortunately, the sex of the subjects not relJOrted, or
whether they were normal. A very large spread of readings was found within
the individual analysis groups, and a pronounced difference between the results
obtained by using the four methods. He thus found: Method I, 877 (593-
1034); Method IV, 881 (590-990); Method Il, 336 (254-400): Method Ill,
317 (153-498) units.
A few authors, for example COHEN et al. (1951)', find that when the
analysis is done by method I there is a significant difference between the values
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Table 1. Serum beta-glucuronidase activity in normal subjects and in
patients suffering from neurological or mental biseases.
I n I S2 I M I t I min.·max.
;roup 1 I
Normal 26 147167 878 275-1993
Multiple Sclerosis 12 155003 946 0.48 460·1440
Psychoses 7 149858 584 -1.71 152·1069
Neuroses 14 213474 1113 1.76 495-2263
Epilepsy 8 148202 1538 4.05*** 799-2068
;roup 2
Normal 25 15456 236 33·415
Multiple Sclerosis
I
11 7993 231 -0.10 145-461
Psychoses 7 16799 149 -1.54 32-425
Neuroses
I
14
I
18036 262
I
0.60 88-553
Epilepsy 8 37040 391 2.14* 76-612
Group 3 I1
Normal 26 8440 158 24-779
Multiple Sclerosis 12 4432 113 -1.69 16-286
Psychoses 4 5046 209 1.30 141-292
Neuroses 14 59324
\
415 3.82** 139·999
Epilepsy 8 63049 434 3.05** 202-991
Group 4
Normal 25 104219 703 253-1459
Multiple Sclerosis 12 110670 955 1.80 566-1535
Psychoses 7 234805 646 -0.34 135-1464
Neuroses 14 185581 877 1.31 443-1955
Epilepsy 8 305696 1136 2.67** 219·1845
(
n=number of cases, s~=variance, M=mean value for activity in units. t=t-test value.
One unit of beta-glucuronidase is the activity resulting in the release of l/-lg phenolphth.
alein per hour under the given experimental conditions. The significant t-values are indicated
by *, ** and ***, depending <m whether the value exceeds the 5 per cent, 1 per cent or 0.1
per cent probability level.
in men (n-16, mean 926, range 640-1360, standard error 44) and women
(n·a3, mean 670, range 300-1100, standard error 41). In the material of the
present investigation, only a small and statistically insignificant difference was
found between the normal men and women examined, so that they are grouped
together both in the normal material and in the separate disease groups.
The table and figures show that in the present material there is also very
great scattering among the values in each separate group.
The analysis results obtained here show more or less the same variations as
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Fig. 1 Serum-glucuronidase in units. Each single point represents one subject
examined. A, Controls (men and women); B, multiple sclerosis, (men
and women); C, epilepsy (men and women); D, Psychosis or mental
disease (women); E, neurosis (men and women). Ordinate: Ordinate:
units.
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found by GOLDSTEIN in determining serum beta-glucuronidase activity by vari-
ous protein-precipitating procedures.
If the values found are evaluated statistically, calculating a mean value and
variance for normal subjects and each patient group, and the standard error the
difference between the normal group and the patient groups is evaluated by the
i-test, it will be found that the group representing patients suffering from epilepsy
differs significantly from the normal group for all of the four methods used.
The other patient groups do not differ significantly from the normal, with
one exception, namely the group of those suffering from neurosis. In this group,
use of method No. Ill. (removal of protein by heat coagulation) shows enzyme
activity deviating sinificantly from normal.
These analyses are made on different days so that a systematic error can
be excluded, as analyses were made on the same days in the case of other pati-
ent groups.
SUMMARY
Using the method given by GOLDSTEIN (1961)9 for the determination of
serum beta-glucuronidase activity, this value was determined in both normal
and patients with epilepsy, neuroses, psychoses and multiple sclerosis. Of the
patient groups examined, the group of those suffering from epilepsy is the only
one showing any difference of statistical significance for all four methods of
determination.
The group of patients suffering from neuroses differs significantly from the
normal group as regards the results got by the method of heat coagulation for
removal of the proteins.
The material is however too small to provide any explanation of the results,
but it appears to show that a determination of serum glucuronidase activity may
be of interest in groups of diseases other than malignant tumors.
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